Opening stock page...
Fetching company snapshot, pricing, and intelligence.
Intelligence coverage: 60%
Basic profile, financials, and market data are shown below. Deep research is building in the background.
AI confidence 70% · prior close shown (market closed)
Immunome Inc. shows decelerating business momentum based on AlphaOS pipeline evidence.
Why it matters: Revenue -100% YoY in Q2 FY2026.
3 signals not yet derived from pipeline evidence
What it means for the thesis — synthesis, not a raw event feed.
Pipeline evidence · 7d ago
IMNM's AlphaOS Signals
Upgrade to Pro for validated historical pattern analysis on IMNM.
Free accounts see more of this; Premium sees all of it.
Reported figures for Immunome Inc. — research only, not investment advice.
Updated
What happened recently for Immunome Inc. (IMNM) — events, not interpretation.
Research & analysis only — not investment advice.
AlphaOS industries
IMNM's AI investment thesis
Upgrade to Premium for IMNM's full multi-agent investment thesis.
Free accounts see more of this; Premium sees all of it.
Unified data coverage and cross-signal highlights — market, SEC, earnings, opportunity
Strengthen intelligence
Prior close
$25.07
Market cap
$2.85B
Profitable
No
Revenue $4.02M
Net income
$-43.40M
FY Sep 5, 2026
Loading Wall Street consensus…
Loading earnings intelligence…
Building technical intelligence snapshot — check back shortly.
Loading market context…
No price history. Sync market data to load charts.
Loading SEC filing intelligence…
No filings ingested yet.
Investment Snapshot above is the primary AlphaOS analysis for Immunome Inc. — structured signals and evidence from proprietary pipelines, not an encyclopedia overview.
Research & analysis only — not investment advice. Price, charts, and filings are above.
Follow Immunome Inc. through AlphaOS's knowledge graph — themes, peers, beneficiaries, earnings, and research answers.
Connected companies and research pages from the AlphaOS knowledge graph.